UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
URGN Price/Volume Stats
| Current price | $10.27 | 52-week high | $20.70 |
| Prev. close | $10.52 | 52-week low | $9.78 |
| Day low | $10.22 | Volume | 262,700 |
| Day high | $10.91 | Avg. volume | 464,518 |
| 50-day MA | $11.46 | Dividend yield | N/A |
| 200-day MA | $13.50 | Market Cap | 240.87M |
URGN Stock Price Chart Interactive Chart >
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
URGN Price Returns
| 1-mo | -3.48% |
| 3-mo | -17.64% |
| 6-mo | -37.26% |
| 1-year | -30.47% |
| 3-year | 34.95% |
| 5-year | -66.21% |
| YTD | -3.57% |
| 2024 | -29.00% |
| 2023 | 69.11% |
| 2022 | -6.73% |
| 2021 | -47.23% |
| 2020 | -46.00% |
Loading social stream, please wait...